Central Ohio's biotech sector has exploded in just five years, with four companies now employing 1,200 people in high-paying jobs. After $600M acquisition, biotech founder finds her new venture ...

Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human ...

After San Francisco biotech company Third Harmonic Bio slashed its staff by half in February, it’s now taking a more drastic step. The inflammatory disease research company’s directors have ...

AmplifyBio, once one of central Ohio's most promising biotech firms, announced Friday that it has shut down. In a posting on its website, the company said the decision followed months of efforts ...

Ltd. iOx specializes in developing liposomal iNKT agonists, with its lead candidate, PORT-2, showing encouraging early clinical results. PRTG Price Action: Portage Biotech stock is up 102.93% at $ ...

There remains much uncertainty about these measures, however. As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news.

For Rituja Suraj Chavan, Managing Director of Valient Biotech Pvt Ltd, starting a company was never just about business—it was about making a difference. The company was founded with a dual ...

Vaccine maker Bharat Biotech International Ltd (BBIL) has set up India’s only vertically integrated, purpose-designed Cell & Gene Therapy (C&GT) Infrastructure & Viral Vector Production facility ...

Biotech companies are innovators, which could translate into growth for your portfolio. It’s important to think long term and pay particular attention to a biotech’s pipeline -- today’s out ...

Advisors, a hedge fund they started in 2000. The fund now manages nearly $22 billion, all invested in biotech stocks. The hedge fund’s Q4 2024 13F holdings report showed $9.36 billion in ...

Spotlight Therapeutics, a Bay Area biotech startup that aimed to “democratize” CRISPR gene editing for patients, has shut down, per new reports. Endpoint reported that Spotlight began laying ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...